Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038220 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00038220 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 40 participants.
The verdict
NCT00038220, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
Interventions
- DRUG Lamivudine
- DRUG Tenofovir DF
- DRUG Efavirenz
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2000-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038220
The ClinicalTrials.gov registry entry for NCT00038220 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00038220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038220 about?
NCT00038220 is a clinical study titled "Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients". The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
What is the current status of trial NCT00038220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2000-07.
What interventions are being tested in trial NCT00038220?
The interventions under investigation include: Lamivudine (DRUG), Tenofovir DF (DRUG), Efavirenz (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00038220?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.